IPF Respiratory Symptoms Management — Current Evidence

Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic disease of the lungs which is characterized by heavy symptom burden, especially in the last year of life. Despite recently established anti-fibrotic treatment IPF prognosis is one of the worst among interstitial lung diseases. In this rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Janowiak, Piotr, Szymanowska-Narloch, Amelia, Siemińska, Alicja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368785/
https://www.ncbi.nlm.nih.gov/pubmed/35966835
http://dx.doi.org/10.3389/fmed.2022.917973
_version_ 1784766248510291968
author Janowiak, Piotr
Szymanowska-Narloch, Amelia
Siemińska, Alicja
author_facet Janowiak, Piotr
Szymanowska-Narloch, Amelia
Siemińska, Alicja
author_sort Janowiak, Piotr
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic disease of the lungs which is characterized by heavy symptom burden, especially in the last year of life. Despite recently established anti-fibrotic treatment IPF prognosis is one of the worst among interstitial lung diseases. In this review available evidence regarding pharmacological and non-pharmacological management of the main IPF symptoms, dyspnea and cough, is presented.
format Online
Article
Text
id pubmed-9368785
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93687852022-08-12 IPF Respiratory Symptoms Management — Current Evidence Janowiak, Piotr Szymanowska-Narloch, Amelia Siemińska, Alicja Front Med (Lausanne) Medicine Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic disease of the lungs which is characterized by heavy symptom burden, especially in the last year of life. Despite recently established anti-fibrotic treatment IPF prognosis is one of the worst among interstitial lung diseases. In this review available evidence regarding pharmacological and non-pharmacological management of the main IPF symptoms, dyspnea and cough, is presented. Frontiers Media S.A. 2022-07-28 /pmc/articles/PMC9368785/ /pubmed/35966835 http://dx.doi.org/10.3389/fmed.2022.917973 Text en Copyright © 2022 Janowiak, Szymanowska-Narloch and Siemińska. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Janowiak, Piotr
Szymanowska-Narloch, Amelia
Siemińska, Alicja
IPF Respiratory Symptoms Management — Current Evidence
title IPF Respiratory Symptoms Management — Current Evidence
title_full IPF Respiratory Symptoms Management — Current Evidence
title_fullStr IPF Respiratory Symptoms Management — Current Evidence
title_full_unstemmed IPF Respiratory Symptoms Management — Current Evidence
title_short IPF Respiratory Symptoms Management — Current Evidence
title_sort ipf respiratory symptoms management — current evidence
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368785/
https://www.ncbi.nlm.nih.gov/pubmed/35966835
http://dx.doi.org/10.3389/fmed.2022.917973
work_keys_str_mv AT janowiakpiotr ipfrespiratorysymptomsmanagementcurrentevidence
AT szymanowskanarlochamelia ipfrespiratorysymptomsmanagementcurrentevidence
AT sieminskaalicja ipfrespiratorysymptomsmanagementcurrentevidence

Ejemplares similares